Lakewood-Amedex’s Second Clinical Trial for DFU Using New Nu-3 Gel Formulation Top Line Results Expected in December 2022 SARASOTA, Fla., April 5, 2022 -...
Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors SARASOTA, Fla., January 25, 2022 — Lakewood-Amedex Inc., a privately held, clinical stage...
Lakewood-Amedex Therapeutics Inc. today announced that Peter B. Corr, Ph.D., has been elected as Chairman of the Board of Directors of the company. Dr....
Lakewood-Amedex Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued a “Notice of Allowance” for two broad patent applications...
LOS ANGELES, CA / ACCESSWIRE / November 29, 2018 / Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, today announced that it will...
SARASOTA, Fla., February 8, 2018 - Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will present at the 2018...
SARASOTA, Fla., December 4, 2017 - Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will be advancing a second...
SARASOTA, Fla., Sept. 27, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced it will present at the BioPharm America Conference...
SARASOTA, Fla., Aug. 31, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that Neil J. Campbell, MA, MBA, and Leonard DeRoma,...
SARASOTA, Fla., Aug. 22, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today the completion of patient treatment...